For the Inventor, By the Inventor

Enter assignee name

Argenx Bv

USPTO Granted Patents = 28

CIPO Patents = 9

EPO Patents = 6

Trademarks = 19

Forward Citations = 95

Loading Chart...

Loading Chart...

91 inventors (with patents filed for the assignee):

Johannes Joseph Wilhelmus De Haard (12 out of 34 patents)

Torsten Dreier (11 out of 27 patents)

Christophe Blanchetot (9 out of 22 patents)

4. Christophe Frederic Jerome Blanchetot (7 out of 12 patents)

5. Peter Ulrichts (5 out of 10 patents)

6. Sebastian Paul Van Der Woning (5 out of 14 patents)

7. Michael Saunders (4 out of 13 patents)

8. Mahan Moshir (4 out of 7 patents)

9. Johannes De Haard (4 out of 11 patents)

10. Hans De Haard (3 out of 20 patents)

11. Karen Silence (3 out of 22 patents)

12. Luc Van Rompaey (3 out of 3 patents)

13. Birgitte Ursø (2 out of 3 patents)

14. Malene Bertelsen (2 out of 3 patents)

15. Tine Skak-Nielsen (2 out of 3 patents)

28 patents: Sort by Forward Citations

1. 12403175 - Methods for treating pemphigus disorders (2025-09-02),

2. 12344678 - FcRn/HSA binding molecules and methods of use (2025-07-01),

3. 12240875 - Use of FCRN antagonists for treatment of generalized myasthenia gravis (2025-03-04),

4. 12202900 - Compositions and methods for treating immune thrombocytopenia (2025-01-21),

5. 12180293 - CD70 combination therapy (2024-12-31),

6. 12071486 - Bispecific antigen binding construct (2024-08-27),

7. 12060413 - Method of preparing pH-dependent antibodies (2024-08-13),

8. 12030949 - Multispecific antibodies against IL-5 and IL-4R (2024-07-09),

9. 11827701 - IL-6 binding molecules (2023-11-28),

10. 11713354 - Galectin-10 antibodies (2023-08-01),

11. 11712468 - CD70 combination therapy (2023-08-01),

12. 11708403 - Antibodies to human complement factor C2B and methods of use (2023-07-25),

13. 11649295 - Asymmetric multispecific antibodies (2023-05-16),

14. 11591388 - Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration (2023-02-28),

15. 11591386 - Antibodies to human complement C2B (2023-02-28),

argenx is a global biotechnology company focused on developing antibody-based therapies to improve the lives of patients with severe autoimmune diseases and cancer. Their proprietary Simple Antibody™ discovery platform allows them to discover and develop differentiated antibody therapeutics by leveraging the diversity of the human immune system. arGEN-X has a deep pipeline of therapeutic programs in various stages of clinical development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

28 Patents

#8 in Ghent

#121 in Belgium

#22,547 in the World

Argenx Bv

Forward Citations = 95

91 inventors:

Johannes Joseph Wilhelmus De Haard (12 out of 34 patents)

Torsten Dreier (11 out of 27 patents)

Christophe Blanchetot (9 out of 22 patents)

4. Christophe Frederic Jerome Blanchetot (7 out of 12 patents)

5. Peter Ulrichts (5 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…